e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
New bronchodilators for COPD management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies
G. Ferguson, G. Feldman, P. Hofbauer, A. Hamilton, L. Allen, L. Korducki, P. Sachs (Livonia, Spartanburg, Ridgefield, Stamford, United States Of America; Weinheim, Germany; Burlington, Canada)
Source:
Annual Congress 2013 –New bronchodilators for COPD management
Session:
New bronchodilators for COPD management
Session type:
Oral Presentation
Number:
187
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Ferguson, G. Feldman, P. Hofbauer, A. Hamilton, L. Allen, L. Korducki, P. Sachs (Livonia, Spartanburg, Ridgefield, Stamford, United States Of America; Weinheim, Germany; Burlington, Canada). Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies. Eur Respir J 2013; 42: Suppl. 57, 187
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
The 24-h FEV
1
time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept